@article {Veiga TeijeiroPA3652, author = {Iria Veiga Teijeiro and Indhira Guzm{\'a}n Peralta and Diego P{\'e}rez Ortiz and Luis P{\'e}rez De Llano and Irene Mart{\'\i}n Robles and Nagore Blanco Cid and David Dacal Rivas and Rafael Golpe G{\'o}mez}, title = {Predictive factors of response to systemic corticosteroids in patients hospitalized with COVID-19 pneumoniae}, volume = {58}, number = {suppl 65}, elocation-id = {PA3652}, year = {2021}, doi = {10.1183/13993003.congress-2021.PA3652}, publisher = {European Respiratory Society}, abstract = {Background: COVID19 pneumonia is probably the most frequent cause of death in this infection. We aimed to identify factors related to favorable response to systemic corticosteroids.Methods: multicenter retrospective post-hoc study of patients with COVID19 pneumonia who received systemic corticosteroids. Multivariate analysis considering independent variables: age, gender, comorbidities (Charlson index), inflammatory status (by CRP), presence of respiratory failure (SpO2 \< 90\%), days from symptom onset to corticosteroid prescription, maximum corticosteroid dose, use of corticosteroid bolus and concomitant tocilizumab. Dependent variable was a composite of death and orotracheal intubation (OTI). Optimal cut-off point was obtained from ROC analysis.Results: 479 patients. Composite outcome was reached in 190(39.6\%)cases. Those who reached it were older, with higher comorbidity load, lower SpO2 and higher CRP. They had shorter interval between symptom onset and corticosteroids~use. They also received more frequently bolus and tocilizumab. Regarding the multivariable logistic regression analysis: older age, use of bolus and use of tocilizumab were significantly associated with a higher risk to reach the composite outcome, while higher SpO2 and a longer interval from symptoms onset to corticosteroid prescription were associated to a lower risk of reaching the adverse outcome. Best cut-off values to rule-out the composite outcome were:<= 73 years(95\%CI:63{\textendash}81.2), SaO2:\>89\%(95\%CI:87{\textendash}89), \>9days for time from symptoms onset to corticosteroid treatment(95\%CI:5.1{\textendash}12).Conclusion: greater mortality benefit in response to corticosteroids if longer duration of symtoms, as Recovery Trial.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3652.This abstract was presented at the 2021 ERS International Congress, in session {\textquotedblleft}Prediction of exacerbations in patients with COPD{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/58/suppl_65/PA3652}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }